FIELD: chemistry.SUBSTANCE: invention relates to a compound of formula (I) or its pharmaceutically acceptable salt, where R1 is an unsubstituted C1-4 alkyl or substituted with 1 methyl or unsubstituted C3 cycloalkyl, p represents 1, q and r represent 0, where the group of formula -(A)-R2 represents 1,2,4-oxadiazolyl substituted with radical R2 in the third position of the ring, and R2 is a substituted with one or more substitutes selected from fluorophenyl, phenyl or F, or unsubstituted C1-4 alkyl； substituted with one or more substitutes selected from methyl, F, CF3 or phenyl, or unsubstituted C3-5 cycloalkyl； substituted with one or more substitutes selected from F, Cl, trifluoromethyl or trifluoromethoxy, or unsubstituted phenyl； substituted with one substitute selected from F or trifluoromethyl, pyridyl. Invention also relates to a compound of formula (IV) or its pharmaceutically acceptable salt, where R1 is an unsubstituted C1-4 alkyl, where the group of formula -(B)-R2 represents 1,2,4-oxadiazolyl substituted with radical R2 in the third position of the ring, and R2 represents an unsubstituted galoC1-4 alkyl. Compounds of formulae (I) and (IV) are intended for preparing a pharmaceutical composition possessing NPY Y5 receptor antagonist activity, containing an effective amount of the compound or its pharmaceutically acceptable salt and a carrier.EFFECT: heterocyclic derivatives with a 5-member aromatic cycle possessing NPY Y5 receptor antagonist activity.9 cl, 38 tblИзобретение относится к соединению формулы (I) или его фармацевтически приемлемой соли, где R1 представляет собой незамещенный С1-4 алкил или замещенный 1 метилом или незамещенный С3 циклоалкил, р представляет собой 1, q и r представляют собой 0, где группа формулы -(А)-R2 представляет собой 1,2,4-оксадиазолил, замещенный радикалом R2 в третьем положении кольца, и R2 представляет собой замещенный одним или несколькими заместителями, выбранными из фторфенила, фенила или F, или незамещенный С1-4 алкил
